Merus N.V.

NasdaqGM:MRUS Rapporto sulle azioni

Cap. di mercato: US$3.7b

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Merus Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Merus ha un patrimonio netto totale di $746.8M e un debito totale di $0.0, che porta il suo rapporto debito/patrimonio netto a 0%. Le sue attività totali e le sue passività totali sono rispettivamente $892.2M e $145.5M.

Informazioni chiave

0%

Rapporto debito/patrimonio netto

US$0

Debito

Indice di copertura degli interessin/a
ContantiUS$787.42m
Patrimonio nettoUS$746.77m
Totale passivitàUS$145.46m
Totale attivitàUS$892.23m

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Aug 14

Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts

Jun 01
Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

May 24

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

May 12
Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans

May 10
Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Mar 01

Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up

Feb 01
Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up

Merus Stock: Rally Seems Overdone

Jan 23

Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?

Jan 14
Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?

Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

Dec 18
Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Sep 19
We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Jun 20
Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

May 24
Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Feb 08
Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Aug 08

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Aug 02

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Jun 30

Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

May 14
Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

Apr 25
Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)

Mar 03
New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)

We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn

Nov 25
We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn

News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts

Aug 08
News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts

Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)

Jul 28
Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Jul 02
We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Merus posts positive efficacy data from early-stage zenocutuzumab cancer study

Jun 04

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $806.6M ) di MRUS superano le sue passività a breve termine ( $80.9M ).

Passività a lungo termine: Le attività a breve termine di MRUS ( $806.6M ) superano le sue passività a lungo termine ( $64.6M ).


Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: MRUS è esente da debiti.

Riduzione del debito: MRUS non aveva debiti 5 anni fa.


Bilancio


Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: MRUS ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow.

Previsione Cash Runway: Dati insufficienti per determinare se MRUS ha una sufficiente pista di cassa se il suo flusso di cassa libero continua a crescere o a ridursi in base ai tassi storici.


Scoprire le aziende sane